Partners4Access, a global leader in pharmaceutical innovation and orphan drug access are proud to announce that Consultant, Olivia Johns has accepted the role of DMD Strategy Advisor.
Despite remarkable scientific progress and strong advocacy from patient groups, the unmet need in Duchenne Muscular Dystrophy (DMD) remains alarmingly high. As rare disease specialists, P4A is committed to maximizing its impact in helping pharmaceutical companies navigate access challenges and bring innovative DMD therapies to patients.
The introduction of the DMD Strategy Advisor (DSA) role ensures dedicated expertise to track the evolving landscape and identify critical barriers to access. Understanding how stakeholders navigate this pivotal and dynamic time will not only support access to DMD treatments but can also provide valuable insights applicable across the rare disease space.
Olivia will be attending the Duchenne UK conference in London on the 28th & 29th of March.
Please get in touch if you’d like to connect in person or online: ojohns@partners4access.com
On accepting the DSA role, Olivia commented:
“Through my work at P4A, and attending the Cure Duchenne conference last year, I have learned a lot about the profound impact DMD has on families and the daily challenges they face. I am extremely pleased to be taking on the role of P4A’s DSA to enhance the support we are able give our clients and the wider Duchenne community”
Managing Partner, Sophie Schmitz commented:
“I am thrilled that Olivia will officially be taking on this new DSA role. Olivia has already been providing invaluable insights to our clients around the world to help shape clinical trial designs, outcome measures, and ensure the disease is clearly understood from patient, caregiver and clinical perspectives. By leveraging her personal commitment to the area and her expertise, we can better support our clients in navigating the challenges of market access for DMD therapies.”
About Partners4Access
Partners4Access is a leading global market access consultancy specializing in rare disease, cell therapy, gene therapy and orphan drug access. With a global presence, we are dedicated to supporting our clients and access to life-changing therapies to patients worldwide.
